Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Bob Kimball who wrote (3513)	3/23/2000 12:32:00 AM
From: Jim Oravetz	Respond to of 3702

USTIN, Calif.--(BW HealthWire)--March 22, 2000--Techniclone Corporation (NASDAQ:TCLN) today announced that Dr. Philip Thorpe Professor of Pharmacology at the University of Texas Southwestern Medical School at Dallas and inventor of the Vascular Targeting Agent ("VTA") technology, presented an update on new developments in his laboratory with this technology at the Keystone Conference held in Salt Lake City recently. Techniclone holds the exclusive worldwide license for this technology from the Board of Regents of the University of Texas system. Dr. Thorpe's presentation entitled "Targeting Coaguligands to Tumor Vasculature" examined the use of several agents designed to treat solid tumors by binding to the tumor blood vessels and subsequently causing a blood clot to form killing the tumors. These so-called "coaguligand" VTA lecules have shown efficacy in several mouse tumor models and are part of the technology that will be examined by the recently announced joint venture with Oxigene Corporation. Specifically, Dr. Thorpe presented anti-tumor experiments performed using coaguligands made by linking antibodies targeted to tumor vasculature markers such as Vascular Cell Adhesion Molecule-1 (VCAM-1) to a truncated version of the human coagulation protein, tissue factor. Once the coaguligand has localized to the tumor blood vessels, a blood clot is formed which results in occlusion of the blood vessel and starvation of the tumor cells. An important finding of the studies was that in order for the coaguligand VTA to be able to induce the formation of blood clots, a second marker known as phosphatidylserine (PS) must also be expressed on the cells that line the tumor blood vessels. " Our experiments have shown that there is the potential for an added margin of safety using these agents therapeutically. It appears that not only is it necessary to have a tumor specific target on the blood vessel but also PS must be present in order for the coagulation process to occur," stated Dr. Phil Thorpe. "This should accelerate the clinical testing of these new drugs," he further stated. The VTA technology was developed to be used as a front-line therapy or in conjunction with other cancer therapeutic agents for the treatment of solid tumors. Preclinical studies, such as those presented at the Keystone meeting, have shown in animal models that treatment with a VTA therapeutic agent can result in significant anti-tumor effects and, in some cases, in complete remission of the treated tumor. The VTA technology targets tumor vasculature to kill the tumor by depriving it of oxygen and essential nutrients. VTA act on the mature blood transporting vessels of the tumor. In contrast, antiangiogenisis agents prevent new tumor blood vessels from growing. These agents in theory could be used together to treat cancer. Techniclone holds over 50 patents either allowed, issued or pending in this area and plans to continue to look for licensing partners for areas in which the Company or the Joint Venture with Oxigene chooses not to focus. John Bonfiglio, Ph.D., President of Techniclone, stated, "We are very excited about the results presented at the Keystone Conference. We feel that understanding the underlying mechanisms and processes involved in VTA function will allow us to more rapidly develop effective and safe VTAs for use in the clinic. This understanding could also lead to wider applications of the VTA technology within the field of cancer and also in other areas." Jim